These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35187143)

  • 1. Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against
    Zhou YF; Sun Z; Wang RL; Li JG; Niu CY; Li XA; Feng YY; Sun J; Liu YH; Liao XP
    Front Vet Sci; 2022; 9():811967. PubMed ID: 35187143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
    Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
    BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-resistance relationship and PK/PD evaluation of danofloxacin against emergence of resistant Pasteurella multocida in an in vitro dynamic model.
    Lu TY; Sun Z; Liang LY; Zhang J; Guo WL; Wang ZY; Sun J; Liao XP; Zhou YF
    J Appl Microbiol; 2024 Jul; 135(7):. PubMed ID: 38925653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of Clinical Breakpoint of Danofloxacin for
    Xu Z; Huang A; Luo X; Zhang P; Huang L; Wang X; Mi K; Fang S; Huang X; Li J; Yuan Z; Hao H
    Antibiotics (Basel); 2021 Jul; 10(7):. PubMed ID: 34356730
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.
    Mi K; Sun D; Li M; Hao H; Zhou K; Liu Z; Yuan Z; Huang L
    Pathogens; 2021 Jan; 10(2):. PubMed ID: 33498972
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal Regimens and Cutoff Evaluation of Tildipirosin Against
    Lei Z; Liu Q; Qi Y; Yang B; Khaliq H; Xiong J; Moku GK; Ahmed S; Li K; Zhang H; Zhang W; Cao J; He Q
    Front Pharmacol; 2018; 9():765. PubMed ID: 30093860
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis.
    Xiao X; Sun J; Chen Y; Huang RJ; Huang T; Qiao GG; Zhou YF; Liu YH
    BMC Vet Res; 2015 Feb; 11():33. PubMed ID: 25889187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.
    Zhang P; Hao H; Li J; Ahmad I; Cheng G; Chen D; Tao Y; Huang L; Wang Y; Dai M; Liu Z; Yuan Z
    Front Microbiol; 2016; 7():385. PubMed ID: 27047487
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Xiao X; Lan W; Zhao Y; Li R; Liu Y; Liu J; Wang Z
    Front Microbiol; 2020; 11():616685. PubMed ID: 33505384
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of danofloxacin in healthy and Pasteurella multocida infected ducks.
    Xiao X; Lan W; Wang Y; Jiang L; Jiang Y; Wang Z
    J Vet Pharmacol Ther; 2018 Dec; 41(6):912-918. PubMed ID: 30182430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
    Dorey L; Pelligand L; Lees P
    BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs.
    Zhang L; Li Y; Wang Y; Sajid A; Ahmed S; Li X
    J Vet Pharmacol Ther; 2018 Oct; 41(5):706-718. PubMed ID: 29696661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against
    Wang RL; Liu P; Chen XF; Yao X; Liao XP; Liu YH; Sun J; Zhou YF
    Front Vet Sci; 2022; 9():945632. PubMed ID: 35898553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic integration of tilmicosin against
    Chen Y; Ji X; Zhang S; Wang W; Zhang H; Ding H
    Front Vet Sci; 2023; 10():1260990. PubMed ID: 37732140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.
    Lees P; Potter T; Pelligand L; Toutain PL
    J Vet Pharmacol Ther; 2018 Feb; 41(1):28-38. PubMed ID: 28736817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.